[HTML][HTML] Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease
H Kawabata, N Tomosugi, J Kanda, Y Tanaka… - …, 2007 - haematologica.org
H Kawabata, N Tomosugi, J Kanda, Y Tanaka, K Yoshizaki, T Uchiyama
Haematologica, 2007•haematologica.orgWe report two cases of multicentric Castleman's disease (MCD) whose serum hepcidin
levels were rapidly down-regulated by administration of tocilizumab, an anti-interleukin 6 (IL-
6) receptor antibody. Our results indicate that IL-6-induced hepcidin over-production may be
involved in the pathophysiology of microcytic anemia commonly observed in this disease.
levels were rapidly down-regulated by administration of tocilizumab, an anti-interleukin 6 (IL-
6) receptor antibody. Our results indicate that IL-6-induced hepcidin over-production may be
involved in the pathophysiology of microcytic anemia commonly observed in this disease.
Abstract
We report two cases of multicentric Castleman’s disease (MCD) whose serum hepcidin levels were rapidly down-regulated by administration of tocilizumab, an anti-interleukin 6 (IL-6) receptor antibody. Our results indicate that IL-6-induced hepcidin over-production may be involved in the pathophysiology of microcytic anemia commonly observed in this disease.
haematologica.org